|Bid||270.41 x 800|
|Ask||270.72 x 800|
|Day's range||265.88 - 271.80|
|52-week range||212.85 - 317.17|
|Beta (5Y monthly)||1.03|
|PE ratio (TTM)||9.63|
|Earnings date||10 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||29 Mar 1994|
|1y target est||342.57|
BURLINGTON, N.C., January 26, 2022--For the millions of people in the United States living with an advanced form of chronic liver disease, simply understanding the potential for future complications could help stave off severe damage and even a transplant. Labcorp (NYSE: LH), a leading global life sciences company, is making this possible by offering the Enhanced Liver Fibrosis (ELF™) test. Developed by Siemens Healthineers, the physician-ordered blood test helps assess the risk of disease progr
With the emergence of the Omicron variant through the Q4 months globally, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered strong top-line contributions.
Although Boston Scientific (BSX) reports margin expansion on a year-over-year basis, the decline in R&D expenses is concerning.